Campaign will focus on empowering patients
impacted by melanoma
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, has joined
forces with television personality, wellness coach and founder of
ALL IN by Teddi, host of the Two T’s in a Pod podcast and stage II
melanoma survivor Teddi Mellencamp Arroyave to raise awareness
around the prevention, detection and management of melanoma, the
deadliest form of skin cancer. The campaign will focus on
empowering patients impacted by the disease.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240722546824/en/
“When I first learned that the weird spot on my back was
melanoma, I was truly in shock,” said Mellencamp Arroyave. “Yes, I
tanned and laid out in the sun as a teen, but as I got older, I
became more aware about taking care of my skin. Skin cancer was not
anything I thought would affect me or that those choices I made
when I was younger would catch up with me. After melanoma was
removed from my shoulder, the 14th lesion resulting in a major
surgery, the gravity of my diagnosis had become evident.
“I want to share my story, both to encourage others to advocate
for their personal health care and to educate anyone and everyone
that this disease does not discriminate, looks different on every
individual, and that taking care of your skin and keeping up with
your skin checks is so important.”
Melanoma will claim nearly 20 American lives each day this year,
making it the most aggressive form of skin cancer.1 Castle’s
DecisionDx®-Melanoma test is designed to provide personalized
information about a patient’s risk of melanoma recurrence,
metastasis and sentinel lymph node positivity based on the biology
of their tumor. This information can help guide important decisions
regarding a patient’s treatment plan and follow-up care that have
been shown to improve patient survival.2,3
Mellencamp Arroyave will be sharing more about her melanoma
journey in a series of conversations on Instagram
(@teddimellencamp) with Aaron S. Farberg, M.D., double
board-certified dermatologist, chief medical officer of Bare
Dermatology in Dallas and assistant professor at the University of
North Texas Health Science Center, and with Morgan England, a stage
III melanoma survivor and patient advocate who received the
DecisionDx-Melanoma test as part of her melanoma care.
“I would tell others with melanoma or any cancer diagnosis that
you have to be your own advocate,” commented England. “And that’s
why I wanted to have the DecisionDx-Melanoma test run on my tumor
biopsy; I learned it could give me more information about my
cancer. There are days when I feel anxious and worried about death
or metastasis, or whether I am on the best treatment pathway for my
disease. When I'm feeling that anxiety, I just read through my test
report. It’s been a way that I have coped with anxiety through this
diagnosis.”
“Melanomas with similar tumor features can have vastly different
biology, which can impact how they behave,” added Farberg. “Is the
tumor more aggressive? Is it likely to return or spread? The
DecisionDx-Melanoma test is designed to provide this vital
information that you can’t always get from a patient’s clinical or
pathologic risk factors … information that helps me make better,
risk-aligned decisions with my patients on how we can treat their
melanoma to help improve the outcome of their disease.”
To learn more about melanoma and Castle’s DecisionDx-Melanoma
test, visit yourmelanoma.com.
About DecisionDx®-Melanoma
DecisionDx-Melanoma is a gene expression profile risk
stratification test. It is designed to inform two clinical
questions in the management of cutaneous melanoma: a patient’s
individual risk of sentinel lymph node (SLN) positivity and a
patient's personal risk of melanoma recurrence and/or metastasis.
By integrating tumor biology with clinical and pathologic factors
using a validated proprietary algorithm, DecisionDx-Melanoma is
designed to provide a comprehensive and clinically actionable
result to guide risk-aligned patient care. DecisionDx-Melanoma has
been shown to be associated with improved patient survival and has
been studied in more than 10,000 patient samples.
DecisionDx-Melanoma’s clinical value is supported by 50
peer-reviewed and published studies, providing confidence in
disease management plans that incorporate the test’s results.
Through March 31, 2024, DecisionDx-Melanoma has been ordered more
than 164,000 times for patients diagnosed with cutaneous
melanoma.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the ability of
DecisionDx-Melanoma test to (i) provide personalized information
about a patient’s risk of melanoma recurrence, metastasis and
sentinel lymph node positivity based on the biology of their tumor
and (ii) help guide important decisions regarding a patient’s
treatment and follow-up care that have been shown to improve
patient survival. The words “believe,” “can,” “may” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking
statements involve risks and uncertainties that could cause our
actual results to differ materially from those in the
forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings or may not support the
results obtained in these studies, including with respect to the
discussion of our tests in this press release; actual application
of our tests may not provide the aforementioned benefits to
patients; and the risks set forth under the heading “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2023, and in our other filings with the SEC. The forward-looking
statements are applicable only as of the date on which they are
made, and we do not assume any obligation to update any
forward-looking statements, except as may be required by law.
- American Academy of Dermatology;
https://www.aad.org/media/stats-skin-cancer; accessed July 19,
2024
- Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression
Profile Testing in Cutaneous Melanoma and Survival Outcomes in a
Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol.
2023; 7. doi: 10.1200/PO.23.00044
- Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging
guided by a 31-gene expression profile assay results in earlier
detection of melanoma with decreased metastatic tumor burden
compared to patients without surveillance imaging studies. Arch
Dermatol Res. 2023. https://doi.org/10.1007/s00403-023-02613-6.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722546824/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
Von Sep 2023 bis Sep 2024